Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript

Core Viewpoint - Aclaris Therapeutics has announced positive interim results from its ATI-052 Phase Ia clinical trial, which involved both single and multiple ascending doses [1]. Group 1: Clinical Trial Results - The conference call was held to review the interim results of the ATI-052 trial, indicating a significant step forward for the company [1]. - The press release detailing these clinical results was made available on the company's Investor Relations website [1]. Group 2: Communication and Presentation - The conference included a presentation with slides that are accessible as a downloadable PDF document during the webcast [2]. - A Q&A session was scheduled to follow the prepared remarks, allowing for further discussion on the trial results [2].